Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial

World Journal of Gastroenterology

Volumn 9, Issue 7, 2003, Pages 1491-1495

  Jaboli, M Francesca ^b   Fabbri, Carlo ^c   Liva, Stefania ^b   Azzaroli, Francesco ^b   Nigro, Giovanni ^b   Giovanelli, Silvia ^b   Ferrara, Francesco ^b   Miracolo, Anna ^b   Marchetto, Sabrina ^b   Montagnani, Marco ^b   Colecchia, Antonio ^b   Festi, Davide ^d   Reggiani, Letizia Bacchi ^b   Roda, Enrico ^b   Mazzella, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c BELLARIA HOSPITAL   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; AMINOTRANSFERASE; AMYLASE; ASPARTIC ACID; CREATINE KINASE; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; METHIONINE; TRIACYLGLYCEROL LIPASE; TYROSINE; VIRUS DNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HAIR LOSS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTRIGLYCERIDEMIA; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROTECTION; PROTEIN VARIANT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0041562706     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i7.1491     Document Type: Article

References (30)

1. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine 1990; 8 (Suppl): S18-S20
2. De Jongh FE, Jansen HL, De Man RA, Hop WC, Schalm SW, Van Blankenstein M. Survival and prognostic indicators of hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635
3. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157
4. Dusheiko GM. Treatment and prevention of chronic viral hepatitis. Pharmacol Ther 1995; 65: 47-73
5. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long term remission of chronic hepatitis B after interferon therapy. Ann Inter Med 1991; 114: 629-634
6. Hoofnagle JH, Lau D. Chronic viral hepatitis-benefits of current therapies. N Eng J Med 1996; 334: 1470-1471
7. Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F, Sostegni R, Pezzoli A, Azzaroli F, Cancellieri C, Montagnani M, Roda E, Rizzetto M. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial. Am J Gastroenterol 1999; 94: 2246-2250
8. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995; 1: 7-15
9. Cui L, Yoon S, Schinazi RF, Sommadossi JP. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-de-oxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555-563
10. Nicoll A, Locarini S. Review: Present and future directions in the treatment of chronic hepatitis B infection. J Gastroentrol Hepatol 1997; 12: 843-854
11. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Eng J Med 1995; 333: 1657-1661
12. Lai CL, Chien RN, Leung NWY, Eta Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one year trial of lamivudine for chronic hepatitis B. N Eng J Med 1998; 339: 61-68
13. Kweon YO, Goodman ZD, Dienstang JL. Lamivudine decreases fibrogenesis in chronic hepatitis B: An immunohistochemical study of paired liver biopsies. Hepatology 2000; 32: 870P
14. Honkoop P, De Man RA, Heitjink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-1157
15. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N. Extended lamivudine re-treatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087
16. Hoofnagle J. Therapy of viral hepatitis. Digestion 1998; 59: 563-578
17. Schiff E, Karayalcin S, Grimm I, Grimm IS, Perrillo RP, Husa P, De Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive hepatitis B in interferon nonresponders. J Hepatol 2003; 38: 818-826
18. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, De Man R, McPhillips P, Johnson M, Williams R, Elias E, Schalm S. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study. J Hepatol 1998; 28: 923-929
19. Heathcote J, Schalm SW, Cianciara J, G Farrell, V Feinmann, M Shermann, AP Dhillon, AE Moorat and DF Gray. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. EASL April 1998, Lisbon
20. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-568
21. Farrell G. Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000; 61: 374-379
22. Scheuer P. Classification of chronic viral hepatitis: A need for reassessment. J Hepatology 1991; 13: 372-374
23. Van Nunen AB, Hansen BE, Mutimer DJ. Viral kinetics during 16 weeks of interferon and lamivudine monotherapy versus interferon-lamivudine combination therapy in chronic hepatitis B patients. Hepatology 2000; 32: 878
24. Brook MG, Petrovic L, McDonald JA, Scheuer PJ, Thomas HC. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J Hepatol 1989; 8: 218-225
25. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716
26. Honkoop P, De Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-639
27. Janssen HLA, Schalm SW, Berk L, De Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis B. J Hepatol 1993; 17(Suppl 3): S47-51
28. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134
29. Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, Gibbs CS, Lam S. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study. Hepatology 2000; 32: 394-399
30. Marques AR, Lau DT, McKenzie R, Straus SE, Hoofnagle JH. Combination therapy with famciclovir and a-interferon for the treatment of chronic hepatitis B. The J Infect Dis 1998; 178: 1483-1487